ACM
APLS

Aquatic Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Aquatic Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-130,828
Closed -$2.96M – 1388
2025
Q3 		$2.96M Sell
130,828
-45,876
-26% -$1.07M 0.05% 399
2025
Q2 		$3.06M Sell
176,704
-39,172
-18% -$725K 0.06% 355
2025
Q1 		$4.72M Buy
215,876
+86,667
+67% +$2.39M 0.12% 224
2024
Q4 		$4.12M Buy
129,209
+126,809
+5,284% +$3.81M 0.11% 236
2024
Q3 		$69.2K Buy
+2,400
New +$88.9K ﹤0.01% 959
2024
Q2 		– Sell
-2,300
Closed -$135K – 1205
2024
Q1 		$135K Buy
+2,300
New +$147K ﹤0.01% 852
2023
Q4 		– Sell
-29,800
Closed -$1.13M – 1309
2023
Q3 		$1.13M Buy
+29,800
New +$1.31M 0.05% 317

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Aquatic Capital Management's APLS Position: Q4 2025 in Review

Aquatic Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 130,828 shares — an estimated $2.96M sold.

Aquatic Capital Management first reported a position in APLS in Q3 2023 and held it in 7 quarters. The position peaked at $4.72M in Q1 2025. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Aquatic Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Aquatic Capital Management sold 130,828 Apellis Pharmaceuticals shares in Q4 2025, an estimated $2.96M.
  • Aquatic Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 7 quarters.
  • Aquatic Capital Management's Apellis Pharmaceuticals position peaked at $4.72M in Q1 2025.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Aquatic Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.